Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), has entered into a collaboration agreement with Revvity, a global life sciences and diagnostics company, to establish the X‑Lab Joint Shared Laboratory – an intelligent, high‑throughput platform designed to advance cutting‑edge antibody drug research and development.
Partnership Overview
| Item | Detail |
|---|---|
| Parties | CTTQ (subsidiary of Sino Biopharmaceutical, HKG: 1177) and Revvity (global life sciences & diagnostics) |
| Announcement Date | 28 Oct 2026 |
| Initiative | X‑Lab Joint Shared Laboratory |
| Model | Intelligent, high‑throughput, closed‑loop wet‑and‑dry laboratory |
| Focus | Antibody drug research and development |
| Scope | Integrated R&D hub spanning target validation, compound screening, antibody drug development, and mechanistic studies |
| Open Access | Universities, research institutes, biotech firms, and early‑stage startups |
Lab Profile & Operating Model
- Wet‑and‑Dry Closed Loop: X‑Lab combines automated wet‑lab experimentation with computational (dry‑lab) analysis in a closed‑loop workflow, enabling rapid design–test–learn cycles that compress early‑stage discovery timelines.
- Shared Platform Concept: Beyond serving Sino Biopharmaceutical’s internal innovation, X‑Lab is designed as an intelligent experimental platform open to the broader biopharmaceutical industry – accessible to universities, research institutes, biotech firms, and early‑stage startups.
- Comprehensive R&D Support: Services include antibody expression, screening and evaluation, and functional validation, directly lowering resource and technical barriers in early‑stage research for smaller innovators.
- Complementary Capabilities: The laboratory leverages CTTQ’s robust drug R&D pipeline and clinical translation experience alongside Revvity’s cutting‑edge capabilities, such as its automated high‑throughput drug screening platform.
Strategic Rationale
- Upstream Innovation Build‑Out: The initiative will help Sino Biopharmaceutical strengthen its upstream innovation capabilities and boost R&D efficiency, shifting value creation earlier in the discovery chain.
- Ecosystem Positioning: By opening X‑Lab to academia and startups, CTTQ positions itself at the center of China’s antibody innovation ecosystem – creating deal flow visibility, partnership opportunities, and platform revenue potential.
- Antibody Focus: The concentration on antibody drugs aligns with one of the most active modalities in global oncology, immunology, and metabolic R&D, where high‑throughput screening and functional validation capacity is a critical bottleneck.
- Global Tooling Alliance: Partnering with Revvity brings internationally established automation and screening infrastructure into the joint laboratory, complementing CTTQ’s domestic clinical translation strengths.
Market Impact & Outlook
- R&D Efficiency Dividend: An integrated hub spanning target validation through mechanistic studies is designed to accelerate candidate progression and reduce early‑attrition costs for Sino Biopharmaceutical’s pipeline.
- Industry Infrastructure: As a shared platform, X‑Lab could become regional infrastructure for early‑stage antibody research, mirroring open‑innovation laboratory models adopted by leading global biopharma hubs.
- Innovation Signaling: The collaboration reinforces Sino Biopharmaceutical’s strategy of pairing in‑house pipeline depth with external technology alliances to sustain long‑term competitiveness in antibody therapeutics.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the X‑Lab Joint Shared Laboratory, including its operational rollout, platform services, and contribution to R&D efficiency and innovation capabilities. Actual results may differ materially due to risks including laboratory build‑out timelines, adoption by external users, technology integration, and research outcomes. No financial terms of the collaboration were disclosed in the company announcement.-Fineline Info & Tech
